nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—RIPK2—Crohn's disease	0.379	0.597	CbGaD
Dasatinib—JAK2—Crohn's disease	0.256	0.403	CbGaD
Dasatinib—KIT—myenteric nerve plexus—Crohn's disease	0.00361	0.0359	CbGeAlD
Dasatinib—PDGFRA—penis—Crohn's disease	0.00256	0.0255	CbGeAlD
Dasatinib—EPHB1—mouth—Crohn's disease	0.00225	0.0224	CbGeAlD
Dasatinib—SRMS—gall bladder—Crohn's disease	0.00204	0.0203	CbGeAlD
Dasatinib—WEE2—lymphoid tissue—Crohn's disease	0.0017	0.0169	CbGeAlD
Dasatinib—TEC—lymphoid tissue—Crohn's disease	0.00129	0.0128	CbGeAlD
Dasatinib—LIMK2—mouth—Crohn's disease	0.00118	0.0117	CbGeAlD
Dasatinib—BMX—epithelium—Crohn's disease	0.0011	0.011	CbGeAlD
Dasatinib—BMX—skin of body—Crohn's disease	0.00105	0.0104	CbGeAlD
Dasatinib—SIK1—mouth—Crohn's disease	0.00103	0.0103	CbGeAlD
Dasatinib—ERBB3—Methyldopa—Mesalazine—Crohn's disease	0.00103	0.438	CbGdCrCtD
Dasatinib—EPHA4—mouth—Crohn's disease	0.00102	0.0101	CbGeAlD
Dasatinib—ERBB3—mouth—Crohn's disease	0.00101	0.01	CbGeAlD
Dasatinib—PTK6—skin of body—Crohn's disease	0.000982	0.00978	CbGeAlD
Dasatinib—PKMYT1—mammalian vulva—Crohn's disease	0.000979	0.00975	CbGeAlD
Dasatinib—STAT5B—epithelium—Crohn's disease	0.000976	0.00972	CbGeAlD
Dasatinib—MAPK14—mouth—Crohn's disease	0.00094	0.00936	CbGeAlD
Dasatinib—STAT5B—skin of body—Crohn's disease	0.000928	0.00925	CbGeAlD
Dasatinib—PTK6—mammalian vulva—Crohn's disease	0.000895	0.00892	CbGeAlD
Dasatinib—FRK—lymphoid tissue—Crohn's disease	0.000869	0.00866	CbGeAlD
Dasatinib—PDGFRA—gall bladder—Crohn's disease	0.000868	0.00865	CbGeAlD
Dasatinib—STAT5B—mammalian vulva—Crohn's disease	0.000847	0.00843	CbGeAlD
Dasatinib—BLK—lymphoid tissue—Crohn's disease	0.000839	0.00835	CbGeAlD
Dasatinib—EPHB2—lymphoid tissue—Crohn's disease	0.000829	0.00826	CbGeAlD
Dasatinib—EPHB2—digestive system—Crohn's disease	0.000819	0.00816	CbGeAlD
Dasatinib—TXK—lymphoid tissue—Crohn's disease	0.000803	0.008	CbGeAlD
Dasatinib—SRMS—digestive system—Crohn's disease	0.000801	0.00798	CbGeAlD
Dasatinib—PTK6—digestive system—Crohn's disease	0.000785	0.00782	CbGeAlD
Dasatinib—BMPR1B—epithelium—Crohn's disease	0.000782	0.00779	CbGeAlD
Dasatinib—STAT5B—lymphoid tissue—Crohn's disease	0.000752	0.00749	CbGeAlD
Dasatinib—STAT5B—digestive system—Crohn's disease	0.000742	0.0074	CbGeAlD
Dasatinib—TEC—lymph node—Crohn's disease	0.000726	0.00723	CbGeAlD
Dasatinib—ZAK—mammalian vulva—Crohn's disease	0.000708	0.00705	CbGeAlD
Dasatinib—KIT—gall bladder—Crohn's disease	0.000694	0.00691	CbGeAlD
Dasatinib—PDGFRB—gall bladder—Crohn's disease	0.000678	0.00675	CbGeAlD
Dasatinib—BTK—mammalian vulva—Crohn's disease	0.000675	0.00672	CbGeAlD
Dasatinib—CSK—smooth muscle tissue—Crohn's disease	0.000637	0.00634	CbGeAlD
Dasatinib—STK35—skin of body—Crohn's disease	0.000633	0.0063	CbGeAlD
Dasatinib—CSK—skin of body—Crohn's disease	0.000628	0.00626	CbGeAlD
Dasatinib—ZAK—lymphoid tissue—Crohn's disease	0.000628	0.00626	CbGeAlD
Dasatinib—TESK1—mammalian vulva—Crohn's disease	0.000626	0.00623	CbGeAlD
Dasatinib—ZAK—digestive system—Crohn's disease	0.000621	0.00618	CbGeAlD
Dasatinib—KIT—mouth—Crohn's disease	0.000617	0.00615	CbGeAlD
Dasatinib—EPHB3—mammalian vulva—Crohn's disease	0.000616	0.00613	CbGeAlD
Dasatinib—STK36—mammalian vulva—Crohn's disease	0.000616	0.00613	CbGeAlD
Dasatinib—RIPK2—epithelium—Crohn's disease	0.000613	0.00611	CbGeAlD
Dasatinib—LYN—lymphoid tissue—Crohn's disease	0.000612	0.00609	CbGeAlD
Dasatinib—EPHA5—digestive system—Crohn's disease	0.000607	0.00605	CbGeAlD
Dasatinib—BTK—lymphoid tissue—Crohn's disease	0.000599	0.00597	CbGeAlD
Dasatinib—LIMK2—mammalian vulva—Crohn's disease	0.000595	0.00593	CbGeAlD
Dasatinib—ERBB3—epithelium—Crohn's disease	0.000587	0.00585	CbGeAlD
Dasatinib—RIPK2—skin of body—Crohn's disease	0.000583	0.00581	CbGeAlD
Dasatinib—CSK—mammalian vulva—Crohn's disease	0.000573	0.00571	CbGeAlD
Dasatinib—EPHB1—lymph node—Crohn's disease	0.00057	0.00567	CbGeAlD
Dasatinib—SIK1—skin of body—Crohn's disease	0.00057	0.00567	CbGeAlD
Dasatinib—HCK—mammalian vulva—Crohn's disease	0.000566	0.00564	CbGeAlD
Dasatinib—ERBB3—skin of body—Crohn's disease	0.000558	0.00556	CbGeAlD
Dasatinib—EPHB2—Diflorasone—Prednisone—Crohn's disease	0.000556	0.236	CbGdCrCtD
Dasatinib—MAPK14—epithelium—Crohn's disease	0.000547	0.00544	CbGeAlD
Dasatinib—EPHB3—digestive system—Crohn's disease	0.00054	0.00538	CbGeAlD
Dasatinib—LIMK2—lymphoid tissue—Crohn's disease	0.000528	0.00526	CbGeAlD
Dasatinib—MAPK14—smooth muscle tissue—Crohn's disease	0.000527	0.00525	CbGeAlD
Dasatinib—MAPK14—skin of body—Crohn's disease	0.00052	0.00518	CbGeAlD
Dasatinib—SIK1—mammalian vulva—Crohn's disease	0.000519	0.00517	CbGeAlD
Dasatinib—EPHB4—epithelium—Crohn's disease	0.000518	0.00516	CbGeAlD
Dasatinib—JAK2—epithelium—Crohn's disease	0.000514	0.00512	CbGeAlD
Dasatinib—EPHA4—mammalian vulva—Crohn's disease	0.000514	0.00512	CbGeAlD
Dasatinib—CSK—lymphoid tissue—Crohn's disease	0.000509	0.00507	CbGeAlD
Dasatinib—EPHA2—epithelium—Crohn's disease	0.000508	0.00506	CbGeAlD
Dasatinib—CSK—digestive system—Crohn's disease	0.000503	0.00501	CbGeAlD
Dasatinib—HCK—lymphoid tissue—Crohn's disease	0.000502	0.005	CbGeAlD
Dasatinib—EPHB4—smooth muscle tissue—Crohn's disease	0.000499	0.00497	CbGeAlD
Dasatinib—HCK—digestive system—Crohn's disease	0.000496	0.00494	CbGeAlD
Dasatinib—JAK2—smooth muscle tissue—Crohn's disease	0.000496	0.00494	CbGeAlD
Dasatinib—JAK2—skin of body—Crohn's disease	0.000489	0.00487	CbGeAlD
Dasatinib—FYN—smooth muscle tissue—Crohn's disease	0.000489	0.00487	CbGeAlD
Dasatinib—FYN—skin of body—Crohn's disease	0.000483	0.00481	CbGeAlD
Dasatinib—BMX—lymph node—Crohn's disease	0.000479	0.00477	CbGeAlD
Dasatinib—MAP4K5—smooth muscle tissue—Crohn's disease	0.000478	0.00476	CbGeAlD
Dasatinib—BLK—lymph node—Crohn's disease	0.000473	0.00471	CbGeAlD
Dasatinib—FGR—mammalian vulva—Crohn's disease	0.000472	0.0047	CbGeAlD
Dasatinib—LCK—mammalian vulva—Crohn's disease	0.000472	0.0047	CbGeAlD
Dasatinib—MAP3K3—skin of body—Crohn's disease	0.000472	0.0047	CbGeAlD
Dasatinib—RIPK2—digestive system—Crohn's disease	0.000467	0.00465	CbGeAlD
Dasatinib—SIK1—lymphoid tissue—Crohn's disease	0.000461	0.00459	CbGeAlD
Dasatinib—FMO3—mammalian vulva—Crohn's disease	0.000456	0.00454	CbGeAlD
Dasatinib—TXK—lymph node—Crohn's disease	0.000453	0.00451	CbGeAlD
Dasatinib—ERBB3—lymphoid tissue—Crohn's disease	0.000452	0.0045	CbGeAlD
Dasatinib—EPHB6—skin of body—Crohn's disease	0.000451	0.00449	CbGeAlD
Dasatinib—EPHB4—mammalian vulva—Crohn's disease	0.000449	0.00448	CbGeAlD
Dasatinib—MAP3K2—lymphoid tissue—Crohn's disease	0.000448	0.00446	CbGeAlD
Dasatinib—ERBB3—digestive system—Crohn's disease	0.000447	0.00445	CbGeAlD
Dasatinib—JAK2—mammalian vulva—Crohn's disease	0.000446	0.00445	CbGeAlD
Dasatinib—YES1—smooth muscle tissue—Crohn's disease	0.000441	0.0044	CbGeAlD
Dasatinib—EPHA2—mammalian vulva—Crohn's disease	0.000441	0.00439	CbGeAlD
Dasatinib—SRC—epithelium—Crohn's disease	0.000441	0.00439	CbGeAlD
Dasatinib—FYN—mammalian vulva—Crohn's disease	0.00044	0.00438	CbGeAlD
Dasatinib—PDGFRA—smooth muscle tissue—Crohn's disease	0.000433	0.00431	CbGeAlD
Dasatinib—MAP4K5—mammalian vulva—Crohn's disease	0.00043	0.00428	CbGeAlD
Dasatinib—MAP3K3—mammalian vulva—Crohn's disease	0.00043	0.00428	CbGeAlD
Dasatinib—SRC—smooth muscle tissue—Crohn's disease	0.000424	0.00423	CbGeAlD
Dasatinib—STAT5B—lymph node—Crohn's disease	0.000424	0.00422	CbGeAlD
Dasatinib—MAPK14—lymphoid tissue—Crohn's disease	0.000421	0.00419	CbGeAlD
Dasatinib—FGR—lymphoid tissue—Crohn's disease	0.000419	0.00418	CbGeAlD
Dasatinib—SRC—skin of body—Crohn's disease	0.000419	0.00417	CbGeAlD
Dasatinib—MAPK14—digestive system—Crohn's disease	0.000416	0.00414	CbGeAlD
Dasatinib—FGR—digestive system—Crohn's disease	0.000414	0.00412	CbGeAlD
Dasatinib—EPHB6—mammalian vulva—Crohn's disease	0.000411	0.00409	CbGeAlD
Dasatinib—YES1—mammalian vulva—Crohn's disease	0.000397	0.00396	CbGeAlD
Dasatinib—JAK2—lymphoid tissue—Crohn's disease	0.000396	0.00395	CbGeAlD
Dasatinib—EPHB4—digestive system—Crohn's disease	0.000394	0.00393	CbGeAlD
Dasatinib—EPHA3—lymph node—Crohn's disease	0.000392	0.0039	CbGeAlD
Dasatinib—EPHA2—lymphoid tissue—Crohn's disease	0.000391	0.0039	CbGeAlD
Dasatinib—JAK2—digestive system—Crohn's disease	0.000391	0.0039	CbGeAlD
Dasatinib—FYN—lymphoid tissue—Crohn's disease	0.000391	0.00389	CbGeAlD
Dasatinib—EPHA2—digestive system—Crohn's disease	0.000387	0.00385	CbGeAlD
Dasatinib—FYN—digestive system—Crohn's disease	0.000386	0.00385	CbGeAlD
Dasatinib—MAP4K5—lymphoid tissue—Crohn's disease	0.000382	0.0038	CbGeAlD
Dasatinib—SIK3—lymph node—Crohn's disease	0.000381	0.0038	CbGeAlD
Dasatinib—CSF1R—smooth muscle tissue—Crohn's disease	0.000381	0.0038	CbGeAlD
Dasatinib—CSF1R—skin of body—Crohn's disease	0.000376	0.00375	CbGeAlD
Dasatinib—Alopecia—Mercaptopurine—Crohn's disease	0.000365	0.0036	CcSEcCtD
Dasatinib—Eczema—Mesalazine—Crohn's disease	0.00036	0.00356	CcSEcCtD
Dasatinib—Malnutrition—Mercaptopurine—Crohn's disease	0.000359	0.00355	CcSEcCtD
Dasatinib—KIT—epithelium—Crohn's disease	0.000359	0.00358	CbGeAlD
Dasatinib—ZAK—lymph node—Crohn's disease	0.000355	0.00353	CbGeAlD
Dasatinib—YES1—lymphoid tissue—Crohn's disease	0.000353	0.00351	CbGeAlD
Dasatinib—MAP2K5—mammalian vulva—Crohn's disease	0.000352	0.0035	CbGeAlD
Dasatinib—PDGFRB—epithelium—Crohn's disease	0.000351	0.00349	CbGeAlD
Dasatinib—Libido decreased—Mesalazine—Crohn's disease	0.000349	0.00345	CcSEcCtD
Dasatinib—YES1—digestive system—Crohn's disease	0.000348	0.00347	CbGeAlD
Dasatinib—KIT—smooth muscle tissue—Crohn's disease	0.000346	0.00345	CbGeAlD
Dasatinib—PDGFRA—lymphoid tissue—Crohn's disease	0.000346	0.00345	CbGeAlD
Dasatinib—CSF1R—mammalian vulva—Crohn's disease	0.000343	0.00342	CbGeAlD
Dasatinib—PDGFRA—digestive system—Crohn's disease	0.000342	0.0034	CbGeAlD
Dasatinib—Atrial fibrillation—Mesalazine—Crohn's disease	0.000342	0.00337	CcSEcCtD
Dasatinib—KIT—skin of body—Crohn's disease	0.000342	0.0034	CbGeAlD
Dasatinib—BMPR1B—lymph node—Crohn's disease	0.00034	0.00339	CbGeAlD
Dasatinib—SRC—lymphoid tissue—Crohn's disease	0.000339	0.00338	CbGeAlD
Dasatinib—BTK—lymph node—Crohn's disease	0.000338	0.00337	CbGeAlD
Dasatinib—PDGFRB—smooth muscle tissue—Crohn's disease	0.000338	0.00337	CbGeAlD
Dasatinib—SRC—digestive system—Crohn's disease	0.000335	0.00334	CbGeAlD
Dasatinib—PDGFRB—skin of body—Crohn's disease	0.000334	0.00332	CbGeAlD
Dasatinib—TNK2—lymph node—Crohn's disease	0.000333	0.00332	CbGeAlD
Dasatinib—Anaemia—Mercaptopurine—Crohn's disease	0.000332	0.00328	CcSEcCtD
Dasatinib—Gastrointestinal haemorrhage—Mesalazine—Crohn's disease	0.000324	0.0032	CcSEcCtD
Dasatinib—CYP1A1—mouth—Crohn's disease	0.000322	0.0032	CbGeAlD
Dasatinib—Disturbance in sexual arousal—Mesalazine—Crohn's disease	0.000321	0.00317	CcSEcCtD
Dasatinib—Affect lability—Mesalazine—Crohn's disease	0.000319	0.00315	CcSEcCtD
Dasatinib—PKMYT1—Danazol—Prednisone—Crohn's disease	0.000315	0.134	CbGdCrCtD
Dasatinib—TESK1—lymph node—Crohn's disease	0.000313	0.00312	CbGeAlD
Dasatinib—Face oedema—Mesalazine—Crohn's disease	0.000313	0.00309	CcSEcCtD
Dasatinib—KIT—mammalian vulva—Crohn's disease	0.000312	0.0031	CbGeAlD
Dasatinib—STK36—lymph node—Crohn's disease	0.000308	0.00307	CbGeAlD
Dasatinib—EPHB3—lymph node—Crohn's disease	0.000308	0.00307	CbGeAlD
Dasatinib—Arthralgia—Mercaptopurine—Crohn's disease	0.000306	0.00302	CcSEcCtD
Dasatinib—CSF1R—lymphoid tissue—Crohn's disease	0.000305	0.00303	CbGeAlD
Dasatinib—PDGFRB—mammalian vulva—Crohn's disease	0.000304	0.00303	CbGeAlD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.000304	0.003	CcSEcCtD
Dasatinib—Blood creatinine increased—Mesalazine—Crohn's disease	0.000303	0.00299	CcSEcCtD
Dasatinib—Pancreatitis—Azathioprine—Crohn's disease	0.000301	0.00297	CcSEcCtD
Dasatinib—ABL1—smooth muscle tissue—Crohn's disease	0.000301	0.003	CbGeAlD
Dasatinib—CSF1R—digestive system—Crohn's disease	0.000301	0.003	CbGeAlD
Dasatinib—LIMK2—lymph node—Crohn's disease	0.000298	0.00297	CbGeAlD
Dasatinib—ABL1—skin of body—Crohn's disease	0.000297	0.00296	CbGeAlD
Dasatinib—Dry skin—Mesalazine—Crohn's disease	0.000297	0.00293	CcSEcCtD
Dasatinib—Oedema—Mercaptopurine—Crohn's disease	0.000293	0.00289	CcSEcCtD
Dasatinib—Breast disorder—Mesalazine—Crohn's disease	0.000293	0.00289	CcSEcCtD
Dasatinib—Pancytopenia—Azathioprine—Crohn's disease	0.000292	0.00288	CcSEcCtD
Dasatinib—Aspartate aminotransferase increased—Mesalazine—Crohn's disease	0.000292	0.00288	CcSEcCtD
Dasatinib—STK35—lymph node—Crohn's disease	0.000289	0.00288	CbGeAlD
Dasatinib—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.000287	0.00283	CcSEcCtD
Dasatinib—CSK—lymph node—Crohn's disease	0.000287	0.00286	CbGeAlD
Dasatinib—Petechiae—Prednisone—Crohn's disease	0.000287	0.00283	CcSEcCtD
Dasatinib—Gastritis—Mesalazine—Crohn's disease	0.000287	0.00283	CcSEcCtD
Dasatinib—Alanine aminotransferase increased—Mesalazine—Crohn's disease	0.000286	0.00282	CcSEcCtD
Dasatinib—Skin disorder—Mercaptopurine—Crohn's disease	0.000285	0.00281	CcSEcCtD
Dasatinib—HCK—lymph node—Crohn's disease	0.000283	0.00282	CbGeAlD
Dasatinib—Abdominal distension—Mesalazine—Crohn's disease	0.000282	0.00278	CcSEcCtD
Dasatinib—ABL2—lymph node—Crohn's disease	0.000282	0.00281	CbGeAlD
Dasatinib—Dysphagia—Mesalazine—Crohn's disease	0.00028	0.00276	CcSEcCtD
Dasatinib—Asthma—Mesalazine—Crohn's disease	0.00028	0.00276	CcSEcCtD
Dasatinib—Anorexia—Mercaptopurine—Crohn's disease	0.00028	0.00276	CcSEcCtD
Dasatinib—KIT—lymphoid tissue—Crohn's disease	0.000277	0.00276	CbGeAlD
Dasatinib—Pneumonia—Azathioprine—Crohn's disease	0.000276	0.00272	CcSEcCtD
Dasatinib—Bronchospasm—Mesalazine—Crohn's disease	0.000275	0.00272	CcSEcCtD
Dasatinib—Pancreatitis—Mesalazine—Crohn's disease	0.000274	0.00271	CcSEcCtD
Dasatinib—Infestation—Azathioprine—Crohn's disease	0.000274	0.0027	CcSEcCtD
Dasatinib—Infestation NOS—Azathioprine—Crohn's disease	0.000274	0.0027	CcSEcCtD
Dasatinib—KIT—digestive system—Crohn's disease	0.000273	0.00272	CbGeAlD
Dasatinib—Angina pectoris—Mesalazine—Crohn's disease	0.000273	0.00269	CcSEcCtD
Dasatinib—ABL1—mammalian vulva—Crohn's disease	0.000271	0.0027	CbGeAlD
Dasatinib—Contusion—Prednisone—Crohn's disease	0.000271	0.00267	CcSEcCtD
Dasatinib—PDGFRB—lymphoid tissue—Crohn's disease	0.00027	0.00269	CbGeAlD
Dasatinib—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.000267	0.00264	CcSEcCtD
Dasatinib—PDGFRB—digestive system—Crohn's disease	0.000267	0.00266	CbGeAlD
Dasatinib—RIPK2—lymph node—Crohn's disease	0.000266	0.00265	CbGeAlD
Dasatinib—Pancytopenia—Mesalazine—Crohn's disease	0.000266	0.00262	CcSEcCtD
Dasatinib—Neutropenia—Mesalazine—Crohn's disease	0.000262	0.00258	CcSEcCtD
Dasatinib—SIK1—lymph node—Crohn's disease	0.00026	0.00259	CbGeAlD
Dasatinib—Upper respiratory tract infection—Mesalazine—Crohn's disease	0.00026	0.00257	CcSEcCtD
Dasatinib—Hepatobiliary disease—Azathioprine—Crohn's disease	0.000259	0.00256	CcSEcCtD
Dasatinib—Pollakiuria—Mesalazine—Crohn's disease	0.000259	0.00255	CcSEcCtD
Dasatinib—EPHA4—lymph node—Crohn's disease	0.000258	0.00257	CbGeAlD
Dasatinib—Photosensitivity reaction—Mesalazine—Crohn's disease	0.000255	0.00252	CcSEcCtD
Dasatinib—CYP1B1—smooth muscle tissue—Crohn's disease	0.000255	0.00254	CbGeAlD
Dasatinib—ERBB3—lymph node—Crohn's disease	0.000255	0.00254	CbGeAlD
Dasatinib—Decreased appetite—Mercaptopurine—Crohn's disease	0.000255	0.00252	CcSEcCtD
Dasatinib—Weight increased—Mesalazine—Crohn's disease	0.000255	0.00251	CcSEcCtD
Dasatinib—Weight decreased—Mesalazine—Crohn's disease	0.000253	0.0025	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.000253	0.0025	CcSEcCtD
Dasatinib—MAP3K2—lymph node—Crohn's disease	0.000253	0.00252	CbGeAlD
Dasatinib—CYP1B1—skin of body—Crohn's disease	0.000252	0.00251	CbGeAlD
Dasatinib—Pneumonia—Mesalazine—Crohn's disease	0.000251	0.00248	CcSEcCtD
Dasatinib—Infestation—Mesalazine—Crohn's disease	0.00025	0.00246	CcSEcCtD
Dasatinib—Infestation NOS—Mesalazine—Crohn's disease	0.00025	0.00246	CcSEcCtD
Dasatinib—Haemoglobin—Azathioprine—Crohn's disease	0.000247	0.00244	CcSEcCtD
Dasatinib—Haemorrhage—Azathioprine—Crohn's disease	0.000246	0.00243	CcSEcCtD
Dasatinib—Renal failure—Mesalazine—Crohn's disease	0.000245	0.00242	CcSEcCtD
Dasatinib—Neuropathy peripheral—Mesalazine—Crohn's disease	0.000245	0.00241	CcSEcCtD
Dasatinib—Stomatitis—Mesalazine—Crohn's disease	0.000243	0.0024	CcSEcCtD
Dasatinib—Conjunctivitis—Mesalazine—Crohn's disease	0.000243	0.00239	CcSEcCtD
Dasatinib—ABL1—lymphoid tissue—Crohn's disease	0.000241	0.0024	CbGeAlD
Dasatinib—Haematuria—Mesalazine—Crohn's disease	0.000238	0.00235	CcSEcCtD
Dasatinib—ABL1—digestive system—Crohn's disease	0.000238	0.00237	CbGeAlD
Dasatinib—MAPK14—lymph node—Crohn's disease	0.000238	0.00237	CbGeAlD
Dasatinib—FGR—lymph node—Crohn's disease	0.000237	0.00236	CbGeAlD
Dasatinib—LCK—lymph node—Crohn's disease	0.000237	0.00236	CbGeAlD
Dasatinib—Hepatobiliary disease—Mesalazine—Crohn's disease	0.000236	0.00233	CcSEcCtD
Dasatinib—Epistaxis—Mesalazine—Crohn's disease	0.000235	0.00232	CcSEcCtD
Dasatinib—Erythema multiforme—Azathioprine—Crohn's disease	0.000233	0.0023	CcSEcCtD
Dasatinib—Body temperature increased—Mercaptopurine—Crohn's disease	0.000232	0.00229	CcSEcCtD
Dasatinib—FMO3—lymph node—Crohn's disease	0.000228	0.00228	CbGeAlD
Dasatinib—TESK1—Dexamethasone—Prednisone—Crohn's disease	0.000226	0.096	CbGdCrCtD
Dasatinib—TESK1—Betamethasone—Prednisone—Crohn's disease	0.000226	0.096	CbGdCrCtD
Dasatinib—Skin exfoliation—Prednisone—Crohn's disease	0.000225	0.00222	CcSEcCtD
Dasatinib—Haemoglobin—Mesalazine—Crohn's disease	0.000225	0.00222	CcSEcCtD
Dasatinib—EPHB4—lymph node—Crohn's disease	0.000225	0.00224	CbGeAlD
Dasatinib—Fluid retention—Prednisone—Crohn's disease	0.000224	0.00221	CcSEcCtD
Dasatinib—Haemorrhage—Mesalazine—Crohn's disease	0.000224	0.00221	CcSEcCtD
Dasatinib—Hepatitis—Mesalazine—Crohn's disease	0.000224	0.00221	CcSEcCtD
Dasatinib—JAK2—lymph node—Crohn's disease	0.000224	0.00223	CbGeAlD
Dasatinib—Immune system disorder—Azathioprine—Crohn's disease	0.000222	0.00219	CcSEcCtD
Dasatinib—Mediastinal disorder—Azathioprine—Crohn's disease	0.000222	0.00219	CcSEcCtD
Dasatinib—Neuropathy—Prednisone—Crohn's disease	0.000222	0.00219	CcSEcCtD
Dasatinib—Urinary tract disorder—Mesalazine—Crohn's disease	0.000221	0.00218	CcSEcCtD
Dasatinib—EPHA2—lymph node—Crohn's disease	0.000221	0.0022	CbGeAlD
Dasatinib—Oedema peripheral—Mesalazine—Crohn's disease	0.000221	0.00218	CcSEcCtD
Dasatinib—Chills—Azathioprine—Crohn's disease	0.000221	0.00218	CcSEcCtD
Dasatinib—FYN—lymph node—Crohn's disease	0.000221	0.0022	CbGeAlD
Dasatinib—Connective tissue disorder—Mesalazine—Crohn's disease	0.00022	0.00217	CcSEcCtD
Dasatinib—Arrhythmia—Azathioprine—Crohn's disease	0.00022	0.00217	CcSEcCtD
Dasatinib—Urethral disorder—Mesalazine—Crohn's disease	0.00022	0.00217	CcSEcCtD
Dasatinib—Alopecia—Azathioprine—Crohn's disease	0.000217	0.00215	CcSEcCtD
Dasatinib—Hypersensitivity—Mercaptopurine—Crohn's disease	0.000216	0.00213	CcSEcCtD
Dasatinib—Oesophagitis—Prednisone—Crohn's disease	0.000216	0.00213	CcSEcCtD
Dasatinib—MAP4K5—lymph node—Crohn's disease	0.000215	0.00215	CbGeAlD
Dasatinib—MAP3K3—lymph node—Crohn's disease	0.000215	0.00215	CbGeAlD
Dasatinib—Ecchymosis—Prednisone—Crohn's disease	0.000213	0.00211	CcSEcCtD
Dasatinib—Erythema multiforme—Mesalazine—Crohn's disease	0.000212	0.00209	CcSEcCtD
Dasatinib—Pulmonary oedema—Prednisone—Crohn's disease	0.00021	0.00207	CcSEcCtD
Dasatinib—Eye disorder—Mesalazine—Crohn's disease	0.000209	0.00207	CcSEcCtD
Dasatinib—Tinnitus—Mesalazine—Crohn's disease	0.000209	0.00206	CcSEcCtD
Dasatinib—Cardiac disorder—Mesalazine—Crohn's disease	0.000208	0.00205	CcSEcCtD
Dasatinib—EPHB6—lymph node—Crohn's disease	0.000206	0.00205	CbGeAlD
Dasatinib—Sepsis—Prednisone—Crohn's disease	0.000205	0.00202	CcSEcCtD
Dasatinib—CYP1B1—lymphoid tissue—Crohn's disease	0.000204	0.00203	CbGeAlD
Dasatinib—Angiopathy—Mesalazine—Crohn's disease	0.000203	0.00201	CcSEcCtD
Dasatinib—Immune system disorder—Mesalazine—Crohn's disease	0.000202	0.002	CcSEcCtD
Dasatinib—Mediastinal disorder—Mesalazine—Crohn's disease	0.000202	0.00199	CcSEcCtD
Dasatinib—CYP1B1—digestive system—Crohn's disease	0.000201	0.00201	CbGeAlD
Dasatinib—Chills—Mesalazine—Crohn's disease	0.000201	0.00198	CcSEcCtD
Dasatinib—Diarrhoea—Mercaptopurine—Crohn's disease	0.000201	0.00198	CcSEcCtD
Dasatinib—YES1—lymph node—Crohn's disease	0.000199	0.00198	CbGeAlD
Dasatinib—Ill-defined disorder—Azathioprine—Crohn's disease	0.000199	0.00196	CcSEcCtD
Dasatinib—Alopecia—Mesalazine—Crohn's disease	0.000198	0.00195	CcSEcCtD
Dasatinib—Thrombophlebitis—Prednisone—Crohn's disease	0.000198	0.00195	CcSEcCtD
Dasatinib—Anaemia—Azathioprine—Crohn's disease	0.000198	0.00195	CcSEcCtD
Dasatinib—Mental disorder—Mesalazine—Crohn's disease	0.000196	0.00194	CcSEcCtD
Dasatinib—PDGFRA—lymph node—Crohn's disease	0.000195	0.00194	CbGeAlD
Dasatinib—Erythema—Mesalazine—Crohn's disease	0.000195	0.00193	CcSEcCtD
Dasatinib—Malaise—Azathioprine—Crohn's disease	0.000193	0.00191	CcSEcCtD
Dasatinib—SRC—lymph node—Crohn's disease	0.000191	0.00191	CbGeAlD
Dasatinib—Dysgeusia—Mesalazine—Crohn's disease	0.000191	0.00189	CcSEcCtD
Dasatinib—Cardiac failure congestive—Prednisone—Crohn's disease	0.000189	0.00186	CcSEcCtD
Dasatinib—Muscle spasms—Mesalazine—Crohn's disease	0.000187	0.00185	CcSEcCtD
Dasatinib—CYP1A1—epithelium—Crohn's disease	0.000187	0.00186	CbGeAlD
Dasatinib—Vomiting—Mercaptopurine—Crohn's disease	0.000186	0.00184	CcSEcCtD
Dasatinib—Rash—Mercaptopurine—Crohn's disease	0.000185	0.00183	CcSEcCtD
Dasatinib—Dermatitis—Mercaptopurine—Crohn's disease	0.000185	0.00182	CcSEcCtD
Dasatinib—Vision blurred—Mesalazine—Crohn's disease	0.000184	0.00181	CcSEcCtD
Dasatinib—Tremor—Mesalazine—Crohn's disease	0.000183	0.0018	CcSEcCtD
Dasatinib—Amnesia—Prednisone—Crohn's disease	0.000182	0.0018	CcSEcCtD
Dasatinib—Arthralgia—Azathioprine—Crohn's disease	0.000182	0.0018	CcSEcCtD
Dasatinib—Myalgia—Azathioprine—Crohn's disease	0.000182	0.0018	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.000181	0.00179	CcSEcCtD
Dasatinib—Ill-defined disorder—Mesalazine—Crohn's disease	0.000181	0.00179	CcSEcCtD
Dasatinib—Anaemia—Mesalazine—Crohn's disease	0.00018	0.00178	CcSEcCtD
Dasatinib—Discomfort—Azathioprine—Crohn's disease	0.00018	0.00178	CcSEcCtD
Dasatinib—CYP1A1—skin of body—Crohn's disease	0.000178	0.00177	CbGeAlD
Dasatinib—MAP2K5—lymph node—Crohn's disease	0.000176	0.00175	CbGeAlD
Dasatinib—Malaise—Mesalazine—Crohn's disease	0.000176	0.00174	CcSEcCtD
Dasatinib—Cardiac failure—Prednisone—Crohn's disease	0.000176	0.00173	CcSEcCtD
Dasatinib—Vertigo—Mesalazine—Crohn's disease	0.000175	0.00173	CcSEcCtD
Dasatinib—Syncope—Mesalazine—Crohn's disease	0.000175	0.00173	CcSEcCtD
Dasatinib—Nausea—Mercaptopurine—Crohn's disease	0.000174	0.00172	CcSEcCtD
Dasatinib—Infection—Azathioprine—Crohn's disease	0.000174	0.00171	CcSEcCtD
Dasatinib—Palpitations—Mesalazine—Crohn's disease	0.000172	0.0017	CcSEcCtD
Dasatinib—CSF1R—lymph node—Crohn's disease	0.000172	0.00171	CbGeAlD
Dasatinib—Loss of consciousness—Mesalazine—Crohn's disease	0.000171	0.00169	CcSEcCtD
Dasatinib—Gastrointestinal haemorrhage—Prednisone—Crohn's disease	0.000171	0.00169	CcSEcCtD
Dasatinib—Thrombocytopenia—Azathioprine—Crohn's disease	0.000171	0.00169	CcSEcCtD
Dasatinib—ABCG2—mammalian vulva—Crohn's disease	0.000171	0.0017	CbGeAlD
Dasatinib—Cough—Mesalazine—Crohn's disease	0.00017	0.00168	CcSEcCtD
Dasatinib—Skin disorder—Azathioprine—Crohn's disease	0.00017	0.00168	CcSEcCtD
Dasatinib—Affect lability—Prednisone—Crohn's disease	0.000169	0.00166	CcSEcCtD
Dasatinib—Hypertension—Mesalazine—Crohn's disease	0.000168	0.00166	CcSEcCtD
Dasatinib—Arthralgia—Mesalazine—Crohn's disease	0.000166	0.00164	CcSEcCtD
Dasatinib—Myalgia—Mesalazine—Crohn's disease	0.000166	0.00164	CcSEcCtD
Dasatinib—Chest pain—Mesalazine—Crohn's disease	0.000166	0.00164	CcSEcCtD
Dasatinib—Anxiety—Mesalazine—Crohn's disease	0.000165	0.00163	CcSEcCtD
Dasatinib—Face oedema—Prednisone—Crohn's disease	0.000165	0.00163	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.000165	0.00163	CcSEcCtD
Dasatinib—Discomfort—Mesalazine—Crohn's disease	0.000164	0.00162	CcSEcCtD
Dasatinib—Hypotension—Azathioprine—Crohn's disease	0.000163	0.00161	CcSEcCtD
Dasatinib—CYP1A1—mammalian vulva—Crohn's disease	0.000162	0.00162	CbGeAlD
Dasatinib—Confusional state—Mesalazine—Crohn's disease	0.00016	0.00158	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.000159	0.00157	CcSEcCtD
Dasatinib—Oedema—Mesalazine—Crohn's disease	0.000159	0.00157	CcSEcCtD
Dasatinib—Infection—Mesalazine—Crohn's disease	0.000158	0.00156	CcSEcCtD
Dasatinib—Dry skin—Prednisone—Crohn's disease	0.000157	0.00155	CcSEcCtD
Dasatinib—Shock—Mesalazine—Crohn's disease	0.000157	0.00155	CcSEcCtD
Dasatinib—Nervous system disorder—Mesalazine—Crohn's disease	0.000156	0.00154	CcSEcCtD
Dasatinib—KIT—lymph node—Crohn's disease	0.000156	0.00155	CbGeAlD
Dasatinib—Hypokalaemia—Prednisone—Crohn's disease	0.000156	0.00154	CcSEcCtD
Dasatinib—Thrombocytopenia—Mesalazine—Crohn's disease	0.000156	0.00154	CcSEcCtD
Dasatinib—Tachycardia—Mesalazine—Crohn's disease	0.000155	0.00153	CcSEcCtD
Dasatinib—Skin disorder—Mesalazine—Crohn's disease	0.000155	0.00153	CcSEcCtD
Dasatinib—Hyperhidrosis—Mesalazine—Crohn's disease	0.000154	0.00152	CcSEcCtD
Dasatinib—PDGFRB—lymph node—Crohn's disease	0.000152	0.00152	CbGeAlD
Dasatinib—Anorexia—Mesalazine—Crohn's disease	0.000152	0.0015	CcSEcCtD
Dasatinib—Muscular weakness—Prednisone—Crohn's disease	0.000151	0.00149	CcSEcCtD
Dasatinib—Alanine aminotransferase increased—Prednisone—Crohn's disease	0.000151	0.00149	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.000151	0.00149	CcSEcCtD
Dasatinib—Abdominal distension—Prednisone—Crohn's disease	0.000149	0.00147	CcSEcCtD
Dasatinib—Hypotension—Mesalazine—Crohn's disease	0.000149	0.00147	CcSEcCtD
Dasatinib—Pancreatitis—Prednisone—Crohn's disease	0.000145	0.00143	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.000145	0.00143	CcSEcCtD
Dasatinib—CYP1A2—digestive system—Crohn's disease	0.000144	0.00144	CbGeAlD
Dasatinib—Feeling abnormal—Azathioprine—Crohn's disease	0.000144	0.00142	CcSEcCtD
Dasatinib—Insomnia—Mesalazine—Crohn's disease	0.000144	0.00142	CcSEcCtD
Dasatinib—Gastrointestinal pain—Azathioprine—Crohn's disease	0.000143	0.00141	CcSEcCtD
Dasatinib—CYP1A1—digestive system—Crohn's disease	0.000142	0.00142	CbGeAlD
Dasatinib—Dyspnoea—Mesalazine—Crohn's disease	0.000142	0.0014	CcSEcCtD
Dasatinib—Somnolence—Mesalazine—Crohn's disease	0.000141	0.0014	CcSEcCtD
Dasatinib—Dyspepsia—Mesalazine—Crohn's disease	0.00014	0.00138	CcSEcCtD
Dasatinib—CYP3A5—digestive system—Crohn's disease	0.000139	0.00139	CbGeAlD
Dasatinib—Neutropenia—Prednisone—Crohn's disease	0.000138	0.00137	CcSEcCtD
Dasatinib—Decreased appetite—Mesalazine—Crohn's disease	0.000138	0.00137	CcSEcCtD
Dasatinib—Body temperature increased—Azathioprine—Crohn's disease	0.000138	0.00136	CcSEcCtD
Dasatinib—Abdominal pain—Azathioprine—Crohn's disease	0.000138	0.00136	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.000137	0.00136	CcSEcCtD
Dasatinib—Fatigue—Mesalazine—Crohn's disease	0.000137	0.00135	CcSEcCtD
Dasatinib—Pain—Mesalazine—Crohn's disease	0.000136	0.00134	CcSEcCtD
Dasatinib—Constipation—Mesalazine—Crohn's disease	0.000136	0.00134	CcSEcCtD
Dasatinib—ABL1—lymph node—Crohn's disease	0.000136	0.00135	CbGeAlD
Dasatinib—Weight increased—Prednisone—Crohn's disease	0.000135	0.00133	CcSEcCtD
Dasatinib—Weight decreased—Prednisone—Crohn's disease	0.000134	0.00132	CcSEcCtD
Dasatinib—Feeling abnormal—Mesalazine—Crohn's disease	0.000131	0.00129	CcSEcCtD
Dasatinib—Acute coronary syndrome—Prednisone—Crohn's disease	0.00013	0.00128	CcSEcCtD
Dasatinib—Gastrointestinal pain—Mesalazine—Crohn's disease	0.00013	0.00128	CcSEcCtD
Dasatinib—Myocardial infarction—Prednisone—Crohn's disease	0.000129	0.00128	CcSEcCtD
Dasatinib—Neuropathy peripheral—Prednisone—Crohn's disease	0.000129	0.00128	CcSEcCtD
Dasatinib—Hypersensitivity—Azathioprine—Crohn's disease	0.000129	0.00127	CcSEcCtD
Dasatinib—Urticaria—Mesalazine—Crohn's disease	0.000126	0.00125	CcSEcCtD
Dasatinib—Abdominal pain—Mesalazine—Crohn's disease	0.000126	0.00124	CcSEcCtD
Dasatinib—Body temperature increased—Mesalazine—Crohn's disease	0.000126	0.00124	CcSEcCtD
Dasatinib—Diarrhoea—Azathioprine—Crohn's disease	0.00012	0.00118	CcSEcCtD
Dasatinib—Haemoglobin—Prednisone—Crohn's disease	0.000119	0.00118	CcSEcCtD
Dasatinib—Haemorrhage—Prednisone—Crohn's disease	0.000119	0.00117	CcSEcCtD
Dasatinib—Hypersensitivity—Mesalazine—Crohn's disease	0.000117	0.00116	CcSEcCtD
Dasatinib—Connective tissue disorder—Prednisone—Crohn's disease	0.000116	0.00115	CcSEcCtD
Dasatinib—Dizziness—Azathioprine—Crohn's disease	0.000116	0.00114	CcSEcCtD
Dasatinib—CYP1B1—lymph node—Crohn's disease	0.000115	0.00115	CbGeAlD
Dasatinib—Asthenia—Mesalazine—Crohn's disease	0.000114	0.00113	CcSEcCtD
Dasatinib—Pruritus—Mesalazine—Crohn's disease	0.000113	0.00111	CcSEcCtD
Dasatinib—Vomiting—Azathioprine—Crohn's disease	0.000111	0.0011	CcSEcCtD
Dasatinib—Eye disorder—Prednisone—Crohn's disease	0.000111	0.00109	CcSEcCtD
Dasatinib—Rash—Azathioprine—Crohn's disease	0.00011	0.00109	CcSEcCtD
Dasatinib—Dermatitis—Azathioprine—Crohn's disease	0.00011	0.00109	CcSEcCtD
Dasatinib—Flushing—Prednisone—Crohn's disease	0.00011	0.00109	CcSEcCtD
Dasatinib—Headache—Azathioprine—Crohn's disease	0.000109	0.00108	CcSEcCtD
Dasatinib—Diarrhoea—Mesalazine—Crohn's disease	0.000109	0.00107	CcSEcCtD
Dasatinib—Angiopathy—Prednisone—Crohn's disease	0.000108	0.00106	CcSEcCtD
Dasatinib—Immune system disorder—Prednisone—Crohn's disease	0.000107	0.00106	CcSEcCtD
Dasatinib—Arrhythmia—Prednisone—Crohn's disease	0.000106	0.00105	CcSEcCtD
Dasatinib—Dizziness—Mesalazine—Crohn's disease	0.000105	0.00104	CcSEcCtD
Dasatinib—Alopecia—Prednisone—Crohn's disease	0.000105	0.00103	CcSEcCtD
Dasatinib—CYP3A4—digestive system—Crohn's disease	0.000104	0.00104	CbGeAlD
Dasatinib—Mental disorder—Prednisone—Crohn's disease	0.000104	0.00103	CcSEcCtD
Dasatinib—Nausea—Azathioprine—Crohn's disease	0.000104	0.00102	CcSEcCtD
Dasatinib—Erythema—Prednisone—Crohn's disease	0.000103	0.00102	CcSEcCtD
Dasatinib—Malnutrition—Prednisone—Crohn's disease	0.000103	0.00102	CcSEcCtD
Dasatinib—Vomiting—Mesalazine—Crohn's disease	0.000101	0.000999	CcSEcCtD
Dasatinib—Rash—Mesalazine—Crohn's disease	0.0001	0.000991	CcSEcCtD
Dasatinib—Dermatitis—Mesalazine—Crohn's disease	0.0001	0.00099	CcSEcCtD
Dasatinib—Headache—Mesalazine—Crohn's disease	9.97e-05	0.000984	CcSEcCtD
Dasatinib—Vision blurred—Prednisone—Crohn's disease	9.72e-05	0.00096	CcSEcCtD
Dasatinib—ABCB1—epithelium—Crohn's disease	9.72e-05	0.000968	CbGeAlD
Dasatinib—Ill-defined disorder—Prednisone—Crohn's disease	9.57e-05	0.000945	CcSEcCtD
Dasatinib—Anaemia—Prednisone—Crohn's disease	9.54e-05	0.000941	CcSEcCtD
Dasatinib—Nausea—Mesalazine—Crohn's disease	9.45e-05	0.000933	CcSEcCtD
Dasatinib—Malaise—Prednisone—Crohn's disease	9.3e-05	0.000919	CcSEcCtD
Dasatinib—Vertigo—Prednisone—Crohn's disease	9.27e-05	0.000915	CcSEcCtD
Dasatinib—Syncope—Prednisone—Crohn's disease	9.25e-05	0.000913	CcSEcCtD
Dasatinib—Loss of consciousness—Prednisone—Crohn's disease	9.07e-05	0.000895	CcSEcCtD
Dasatinib—Convulsion—Prednisone—Crohn's disease	8.94e-05	0.000882	CcSEcCtD
Dasatinib—Hypertension—Prednisone—Crohn's disease	8.91e-05	0.000879	CcSEcCtD
Dasatinib—Myalgia—Prednisone—Crohn's disease	8.78e-05	0.000867	CcSEcCtD
Dasatinib—Arthralgia—Prednisone—Crohn's disease	8.78e-05	0.000867	CcSEcCtD
Dasatinib—Anxiety—Prednisone—Crohn's disease	8.75e-05	0.000864	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	8.72e-05	0.000861	CcSEcCtD
Dasatinib—Discomfort—Prednisone—Crohn's disease	8.68e-05	0.000857	CcSEcCtD
Dasatinib—ABCG2—lymph node—Crohn's disease	8.57e-05	0.000853	CbGeAlD
Dasatinib—ABCB1—mammalian vulva—Crohn's disease	8.43e-05	0.00084	CbGeAlD
Dasatinib—Oedema—Prednisone—Crohn's disease	8.42e-05	0.000831	CcSEcCtD
Dasatinib—Infection—Prednisone—Crohn's disease	8.37e-05	0.000826	CcSEcCtD
Dasatinib—Shock—Prednisone—Crohn's disease	8.28e-05	0.000818	CcSEcCtD
Dasatinib—Nervous system disorder—Prednisone—Crohn's disease	8.26e-05	0.000815	CcSEcCtD
Dasatinib—Tachycardia—Prednisone—Crohn's disease	8.22e-05	0.000811	CcSEcCtD
Dasatinib—Skin disorder—Prednisone—Crohn's disease	8.18e-05	0.000807	CcSEcCtD
Dasatinib—Hyperhidrosis—Prednisone—Crohn's disease	8.14e-05	0.000804	CcSEcCtD
Dasatinib—CYP1A1—lymph node—Crohn's disease	8.13e-05	0.00081	CbGeAlD
Dasatinib—Anorexia—Prednisone—Crohn's disease	8.03e-05	0.000792	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Prednisone—Crohn's disease	7.67e-05	0.000757	CcSEcCtD
Dasatinib—Insomnia—Prednisone—Crohn's disease	7.62e-05	0.000752	CcSEcCtD
Dasatinib—ABCB1—lymphoid tissue—Crohn's disease	7.49e-05	0.000746	CbGeAlD
Dasatinib—Dyspepsia—Prednisone—Crohn's disease	7.41e-05	0.000732	CcSEcCtD
Dasatinib—ABCB1—digestive system—Crohn's disease	7.4e-05	0.000737	CbGeAlD
Dasatinib—Decreased appetite—Prednisone—Crohn's disease	7.32e-05	0.000723	CcSEcCtD
Dasatinib—Fatigue—Prednisone—Crohn's disease	7.26e-05	0.000717	CcSEcCtD
Dasatinib—Constipation—Prednisone—Crohn's disease	7.2e-05	0.000711	CcSEcCtD
Dasatinib—Feeling abnormal—Prednisone—Crohn's disease	6.94e-05	0.000685	CcSEcCtD
Dasatinib—Gastrointestinal pain—Prednisone—Crohn's disease	6.89e-05	0.00068	CcSEcCtD
Dasatinib—Urticaria—Prednisone—Crohn's disease	6.69e-05	0.00066	CcSEcCtD
Dasatinib—Abdominal pain—Prednisone—Crohn's disease	6.66e-05	0.000657	CcSEcCtD
Dasatinib—Body temperature increased—Prednisone—Crohn's disease	6.66e-05	0.000657	CcSEcCtD
Dasatinib—Hypersensitivity—Prednisone—Crohn's disease	6.2e-05	0.000612	CcSEcCtD
Dasatinib—Asthenia—Prednisone—Crohn's disease	6.04e-05	0.000596	CcSEcCtD
Dasatinib—Pruritus—Prednisone—Crohn's disease	5.96e-05	0.000588	CcSEcCtD
Dasatinib—Diarrhoea—Prednisone—Crohn's disease	5.76e-05	0.000569	CcSEcCtD
Dasatinib—Dizziness—Prednisone—Crohn's disease	5.57e-05	0.00055	CcSEcCtD
Dasatinib—Vomiting—Prednisone—Crohn's disease	5.35e-05	0.000529	CcSEcCtD
Dasatinib—Rash—Prednisone—Crohn's disease	5.31e-05	0.000524	CcSEcCtD
Dasatinib—Dermatitis—Prednisone—Crohn's disease	5.3e-05	0.000524	CcSEcCtD
Dasatinib—Headache—Prednisone—Crohn's disease	5.28e-05	0.000521	CcSEcCtD
Dasatinib—Nausea—Prednisone—Crohn's disease	5e-05	0.000494	CcSEcCtD
Dasatinib—ABCB1—lymph node—Crohn's disease	4.22e-05	0.000421	CbGeAlD
Dasatinib—SRC—Disease—SMAD3—Crohn's disease	3.25e-06	2.01e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—CD4—Crohn's disease	3.25e-06	2.01e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TYK2—Crohn's disease	3.25e-06	2.01e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—TYK2—Crohn's disease	3.25e-06	2.01e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—TYK2—Crohn's disease	3.24e-06	2e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—SMAD3—Crohn's disease	3.21e-06	1.98e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—ICAM1—Crohn's disease	3.2e-06	1.98e-05	CbGpPWpGaD
Dasatinib—MAP3K3—Immune System—IL6—Crohn's disease	3.19e-06	1.98e-05	CbGpPWpGaD
Dasatinib—KIT—Innate Immune System—IL6—Crohn's disease	3.19e-06	1.97e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—UBE2D1—Crohn's disease	3.19e-06	1.97e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—IL1B—Crohn's disease	3.17e-06	1.96e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—CD4—Crohn's disease	3.17e-06	1.96e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—TYK2—Crohn's disease	3.17e-06	1.96e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—JAK2—Crohn's disease	3.16e-06	1.96e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—TYK2—Crohn's disease	3.15e-06	1.95e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—PTGS2—Crohn's disease	3.15e-06	1.95e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—SMAD3—Crohn's disease	3.14e-06	1.94e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TYK2—Crohn's disease	3.13e-06	1.94e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—STAT3—Crohn's disease	3.13e-06	1.94e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—STAT3—Crohn's disease	3.13e-06	1.94e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—TYK2—Crohn's disease	3.12e-06	1.93e-05	CbGpPWpGaD
Dasatinib—JAK2—GPCR downstream signaling—CXCL8—Crohn's disease	3.11e-06	1.93e-05	CbGpPWpGaD
Dasatinib—BTK—Immune System—IL6—Crohn's disease	3.11e-06	1.92e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—JAK2—Crohn's disease	3.1e-06	1.92e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—SMAD3—Crohn's disease	3.09e-06	1.91e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—CXCL8—Crohn's disease	3.09e-06	1.91e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—RIPK2—Crohn's disease	3.09e-06	1.91e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—JAK2—Crohn's disease	3.09e-06	1.91e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—CRP—Crohn's disease	3.08e-06	1.9e-05	CbGpPWpGaD
Dasatinib—SRC—Axon guidance—IL6—Crohn's disease	3.06e-06	1.9e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	3.03e-06	1.88e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—IFNG—Crohn's disease	3.03e-06	1.88e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—JAK2—Crohn's disease	3.02e-06	1.87e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Innate Immune System—IL6—Crohn's disease	3.02e-06	1.87e-05	CbGpPWpGaD
Dasatinib—LYN—Developmental Biology—IL6—Crohn's disease	3.01e-06	1.86e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL3—Crohn's disease	3.01e-06	1.86e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—JAK2—Crohn's disease	3.01e-06	1.86e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—TYK2—Crohn's disease	3e-06	1.86e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—IL1B—Crohn's disease	3e-06	1.86e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—CD4—Crohn's disease	3e-06	1.86e-05	CbGpPWpGaD
Dasatinib—ABL1—Developmental Biology—IL6—Crohn's disease	3e-06	1.86e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—FADS1—Crohn's disease	2.99e-06	1.85e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—TYK2—Crohn's disease	2.99e-06	1.85e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—JAK2—Crohn's disease	2.99e-06	1.85e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—SOCS1—Crohn's disease	2.98e-06	1.84e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—PTGS2—Crohn's disease	2.98e-06	1.84e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—SMAD3—Crohn's disease	2.98e-06	1.84e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—JAK2—Crohn's disease	2.98e-06	1.84e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—STAT3—Crohn's disease	2.98e-06	1.84e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL2RA—Crohn's disease	2.97e-06	1.84e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—IFNG—Crohn's disease	2.97e-06	1.84e-05	CbGpPWpGaD
Dasatinib—FYN—Developmental Biology—IL6—Crohn's disease	2.97e-06	1.84e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—MTMR3—Crohn's disease	2.97e-06	1.84e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—TYK2—Crohn's disease	2.97e-06	1.84e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—IFNG—Crohn's disease	2.95e-06	1.83e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—TLR4—Crohn's disease	2.95e-06	1.83e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—SMAD3—Crohn's disease	2.94e-06	1.82e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—CD4—Crohn's disease	2.93e-06	1.81e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—IFNG—Crohn's disease	2.92e-06	1.81e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—RASGRP1—Crohn's disease	2.91e-06	1.8e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL2RA—Crohn's disease	2.91e-06	1.8e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—TYK2—Crohn's disease	2.88e-06	1.78e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—JAK2—Crohn's disease	2.87e-06	1.77e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—CD4—Crohn's disease	2.87e-06	1.77e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL2RA—Crohn's disease	2.86e-06	1.77e-05	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—IL6—Crohn's disease	2.86e-06	1.77e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—CD4—Crohn's disease	2.85e-06	1.77e-05	CbGpPWpGaD
Dasatinib—HCK—Immune System—IL6—Crohn's disease	2.85e-06	1.76e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—JAK2—Crohn's disease	2.85e-06	1.76e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—ICAM1—Crohn's disease	2.83e-06	1.75e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—CXCL8—Crohn's disease	2.83e-06	1.75e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—CXCL8—Crohn's disease	2.83e-06	1.75e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—CD4—Crohn's disease	2.82e-06	1.75e-05	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—IL6—Crohn's disease	2.82e-06	1.74e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IFNG—Crohn's disease	2.81e-06	1.74e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GPX4—Crohn's disease	2.8e-06	1.73e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IFNG—Crohn's disease	2.78e-06	1.72e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL2RA—Crohn's disease	2.76e-06	1.71e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—JAK2—Crohn's disease	2.75e-06	1.7e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TYK2—Crohn's disease	2.75e-06	1.7e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—TYK2—Crohn's disease	2.74e-06	1.69e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—CXCL8—Crohn's disease	2.73e-06	1.69e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL2RA—Crohn's disease	2.72e-06	1.68e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Innate Immune System—IL6—Crohn's disease	2.72e-06	1.68e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—CD4—Crohn's disease	2.72e-06	1.68e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—TNF—Crohn's disease	2.71e-06	1.68e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GCKR—Crohn's disease	2.71e-06	1.68e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—IL1B—Crohn's disease	2.7e-06	1.67e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—CD4—Crohn's disease	2.7e-06	1.67e-05	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—IL6—Crohn's disease	2.69e-06	1.66e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—PTGS2—Crohn's disease	2.68e-06	1.66e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—CD4—Crohn's disease	2.68e-06	1.66e-05	CbGpPWpGaD
Dasatinib—LYN—Innate Immune System—IL6—Crohn's disease	2.66e-06	1.65e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—STAT3—Crohn's disease	2.66e-06	1.64e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	2.65e-06	1.64e-05	CbGpPWpGaD
Dasatinib—ABL1—Innate Immune System—IL6—Crohn's disease	2.65e-06	1.64e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—IL1B—Crohn's disease	2.65e-06	1.64e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—SOCS1—Crohn's disease	2.64e-06	1.63e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—IL1B—Crohn's disease	2.63e-06	1.63e-05	CbGpPWpGaD
Dasatinib—HCK—Disease—IL6—Crohn's disease	2.63e-06	1.63e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—JAK2—Crohn's disease	2.62e-06	1.62e-05	CbGpPWpGaD
Dasatinib—FYN—Innate Immune System—IL6—Crohn's disease	2.62e-06	1.62e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—IL1B—Crohn's disease	2.61e-06	1.61e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—CD4—Crohn's disease	2.61e-06	1.61e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—TYK2—Crohn's disease	2.6e-06	1.61e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—PTGS2—Crohn's disease	2.59e-06	1.6e-05	CbGpPWpGaD
Dasatinib—BLK—Immune System—IL6—Crohn's disease	2.58e-06	1.6e-05	CbGpPWpGaD
Dasatinib—FGR—Immune System—IL6—Crohn's disease	2.58e-06	1.59e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—SMAD3—Crohn's disease	2.57e-06	1.59e-05	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—IL6—Crohn's disease	2.52e-06	1.56e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—STAT3—Crohn's disease	2.52e-06	1.56e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL1B—Crohn's disease	2.51e-06	1.55e-05	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—IL6—Crohn's disease	2.49e-06	1.54e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—STAT3—Crohn's disease	2.49e-06	1.54e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—JAK2—Crohn's disease	2.48e-06	1.53e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL1B—Crohn's disease	2.48e-06	1.53e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—CD4—Crohn's disease	2.48e-06	1.53e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—PTGS2—Crohn's disease	2.46e-06	1.52e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TYK2—Crohn's disease	2.45e-06	1.52e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—STAT3—Crohn's disease	2.45e-06	1.52e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—IFNG—Crohn's disease	2.43e-06	1.51e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—IL6—Crohn's disease	2.4e-06	1.49e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—TYK2—Crohn's disease	2.4e-06	1.48e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—CXCL8—Crohn's disease	2.39e-06	1.48e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL2RA—Crohn's disease	2.38e-06	1.47e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—IL6—Crohn's disease	2.37e-06	1.47e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—CD4—Crohn's disease	2.35e-06	1.45e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—JAK2—Crohn's disease	2.34e-06	1.45e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—IL6—Crohn's disease	2.33e-06	1.44e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TYK2—Crohn's disease	2.32e-06	1.44e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—STAT3—Crohn's disease	2.32e-06	1.44e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—FADS1—Crohn's disease	2.31e-06	1.43e-05	CbGpPWpGaD
Dasatinib—ABCB1—Transmembrane transport of small molecules—ALB—Crohn's disease	2.3e-06	1.43e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—TYK2—Crohn's disease	2.3e-06	1.42e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—JAK2—Crohn's disease	2.29e-06	1.42e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—SMAD3—Crohn's disease	2.28e-06	1.41e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—STAT3—Crohn's disease	2.27e-06	1.41e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—STAT3—Crohn's disease	2.27e-06	1.4e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—STAT3—Crohn's disease	2.22e-06	1.37e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—JAK2—Crohn's disease	2.22e-06	1.37e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—STAT3—Crohn's disease	2.21e-06	1.37e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—ALB—Crohn's disease	2.19e-06	1.36e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—JAK2—Crohn's disease	2.19e-06	1.36e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—STAT3—Crohn's disease	2.19e-06	1.36e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—IL6—Crohn's disease	2.19e-06	1.35e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—IL6—Crohn's disease	2.19e-06	1.35e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—STAT3—Crohn's disease	2.18e-06	1.35e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—IL6—Crohn's disease	2.18e-06	1.35e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL1B—Crohn's disease	2.17e-06	1.34e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—CD4—Crohn's disease	2.17e-06	1.34e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GPX4—Crohn's disease	2.16e-06	1.34e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—IFNG—Crohn's disease	2.15e-06	1.33e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—PTGS2—Crohn's disease	2.15e-06	1.33e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CXCL8—Crohn's disease	2.14e-06	1.32e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—TYK2—Crohn's disease	2.12e-06	1.31e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL2RA—Crohn's disease	2.11e-06	1.31e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—STAT3—Crohn's disease	2.1e-06	1.3e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TYK2—Crohn's disease	2.09e-06	1.29e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—STAT3—Crohn's disease	2.09e-06	1.29e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GCKR—Crohn's disease	2.09e-06	1.29e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—CD4—Crohn's disease	2.08e-06	1.29e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—IL6—Crohn's disease	2.08e-06	1.29e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—STAT3—Crohn's disease	2.08e-06	1.28e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TYK2—Crohn's disease	2.05e-06	1.27e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—JAK2—Crohn's disease	2.03e-06	1.25e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CXCL8—Crohn's disease	2.02e-06	1.25e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TYK2—Crohn's disease	2.02e-06	1.25e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—STAT3—Crohn's disease	2.02e-06	1.25e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—ALB—Crohn's disease	2e-06	1.24e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—JAK2—Crohn's disease	2e-06	1.24e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—JAK2—Crohn's disease	1.95e-06	1.21e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TYK2—Crohn's disease	1.94e-06	1.2e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	1.93e-06	1.2e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—IL6—Crohn's disease	1.93e-06	1.19e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—JAK2—Crohn's disease	1.92e-06	1.19e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—STAT3—Crohn's disease	1.92e-06	1.19e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL1B—Crohn's disease	1.92e-06	1.19e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—CD4—Crohn's disease	1.92e-06	1.19e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PTGS2—Crohn's disease	1.92e-06	1.19e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TYK2—Crohn's disease	1.92e-06	1.19e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—STAT3—Crohn's disease	1.92e-06	1.19e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—PTGS2—Crohn's disease	1.91e-06	1.18e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—IL6—Crohn's disease	1.86e-06	1.15e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—JAK2—Crohn's disease	1.85e-06	1.15e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CXCL8—Crohn's disease	1.82e-06	1.13e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—STAT3—Crohn's disease	1.82e-06	1.13e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CXCL8—Crohn's disease	1.78e-06	1.1e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—IL6—Crohn's disease	1.76e-06	1.09e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CXCL8—Crohn's disease	1.76e-06	1.09e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PTGS2—Crohn's disease	1.75e-06	1.08e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—IL6—Crohn's disease	1.74e-06	1.07e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—STAT3—Crohn's disease	1.72e-06	1.06e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—IL6—Crohn's disease	1.71e-06	1.06e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.69e-06	1.05e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CXCL8—Crohn's disease	1.69e-06	1.05e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TYK2—Crohn's disease	1.68e-06	1.04e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—STAT3—Crohn's disease	1.68e-06	1.04e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CXCL8—Crohn's disease	1.67e-06	1.03e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—STAT3—Crohn's disease	1.63e-06	1.01e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—IL6—Crohn's disease	1.62e-06	1e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—STAT3—Crohn's disease	1.61e-06	9.96e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—JAK2—Crohn's disease	1.6e-06	9.91e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—IL6—Crohn's disease	1.59e-06	9.83e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—IL6—Crohn's disease	1.59e-06	9.82e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—IL6—Crohn's disease	1.58e-06	9.8e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—IL6—Crohn's disease	1.55e-06	9.59e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—IL6—Crohn's disease	1.54e-06	9.55e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—IL6—Crohn's disease	1.53e-06	9.47e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—IL6—Crohn's disease	1.53e-06	9.44e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TYK2—Crohn's disease	1.49e-06	9.2e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—STAT3—Crohn's disease	1.49e-06	9.2e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL6—Crohn's disease	1.47e-06	9.09e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—STAT3—Crohn's disease	1.47e-06	9.07e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CXCL8—Crohn's disease	1.46e-06	9.05e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—IL6—Crohn's disease	1.46e-06	9.04e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL6—Crohn's disease	1.45e-06	8.97e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—STAT3—Crohn's disease	1.43e-06	8.88e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—ALB—Crohn's disease	1.43e-06	8.85e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—JAK2—Crohn's disease	1.42e-06	8.78e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—STAT3—Crohn's disease	1.41e-06	8.74e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—IL6—Crohn's disease	1.41e-06	8.72e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—STAT3—Crohn's disease	1.36e-06	8.42e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—ALB—Crohn's disease	1.35e-06	8.36e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—IL6—Crohn's disease	1.34e-06	8.32e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—STAT3—Crohn's disease	1.34e-06	8.31e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—IL6—Crohn's disease	1.34e-06	8.29e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CXCL8—Crohn's disease	1.29e-06	8.01e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL6—Crohn's disease	1.27e-06	7.86e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTGS2—Crohn's disease	1.25e-06	7.74e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IL6—Crohn's disease	1.2e-06	7.43e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTGS2—Crohn's disease	1.18e-06	7.32e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—STAT3—Crohn's disease	1.18e-06	7.28e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—IL6—Crohn's disease	1.17e-06	7.26e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IL6—Crohn's disease	1.14e-06	7.03e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL6—Crohn's disease	1.12e-06	6.96e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—ALB—Crohn's disease	1.08e-06	6.68e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—STAT3—Crohn's disease	1.04e-06	6.44e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—IL6—Crohn's disease	1.04e-06	6.43e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL6—Crohn's disease	1.02e-06	6.33e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL6—Crohn's disease	1e-06	6.2e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL6—Crohn's disease	9.87e-07	6.1e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL6—Crohn's disease	9.5e-07	5.88e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTGS2—Crohn's disease	9.44e-07	5.84e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL6—Crohn's disease	9.38e-07	5.8e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ALB—Crohn's disease	8.62e-07	5.33e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL6—Crohn's disease	8.21e-07	5.08e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTGS2—Crohn's disease	7.54e-07	4.66e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL6—Crohn's disease	7.27e-07	4.5e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ALB—Crohn's disease	6.65e-07	4.12e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTGS2—Crohn's disease	5.82e-07	3.6e-06	CbGpPWpGaD
